ReviewAmerican journal of cancer research2026

PARP inhibitor maintenance in first-line ovarian cancer therapy: emerging standards and strategies to overcome resistance.

Huizhen ChenPubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.